Arvinas to present Phase 1 biomarker data for ARV-102 Parkinson’s trial at 2026 MDS Congress
ARVN•Arvinas scheduled Phase 1 biomarker data for its ARV-102 Parkinson’s trial for presentation on Oct. 7, 2026, with new oculomotor findings; results have not yet been presented.
1. Presentation scheduled
Arvinas scheduled late-breaking Phase 1 biomarker data for ARV-102 in Parkinson’s disease for presentation on Oct. 7, 2026, at the 2026 MDS Congress. The company flagged new oculomotor findings alongside the trial’s biomarker readouts; results have not yet been presented.
